163 related articles for article (PubMed ID: 31585260)
1. Design, synthesis and evaluation of some 1,6-disubstituted-1H-benzo[d]imidazoles derivatives targeted PI3K as anticancer agents.
Ding HW; Yu L; Bai MX; Qin XC; Song MT; Zhao QC
Bioorg Chem; 2019 Dec; 93():103283. PubMed ID: 31585260
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and anticancer evaluation of novel 1H-benzo[d]imidazole derivatives of dehydroabietic acid as PI3Kα inhibitors.
Yang YQ; Chen H; Liu QS; Sun Y; Gu W
Bioorg Chem; 2020 Jul; 100():103845. PubMed ID: 32344183
[TBL] [Abstract][Full Text] [Related]
3. Discovery and synthesis of 2-amino-1-methyl-1H-imidazol-4(5H)-ones as GPCR ligands; an approach to develop breast cancer drugs via GPCR associated PAR1 and PI3Kinase inhibition mechanism.
Ashok SR; Shivananda MK; Manikandan A; Chandrasekaran R
Bioorg Chem; 2019 May; 86():641-651. PubMed ID: 30822721
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and Biological Evaluation of Imidazo[1,2-
Yu Y; Han Y; Zhang F; Gao Z; Zhu T; Dong S; Ma M
J Med Chem; 2020 Mar; 63(6):3028-3046. PubMed ID: 32069401
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition.
Yang H; Li Q; Su M; Luo F; Liu Y; Wang D; Fan Y
Bioorg Med Chem; 2021 Sep; 46():116346. PubMed ID: 34403956
[TBL] [Abstract][Full Text] [Related]
6. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of new thieno[2,3-
Elmenier FM; Lasheen DS; Abouzid KAM
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):315-332. PubMed ID: 34955086
[TBL] [Abstract][Full Text] [Related]
8. Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates containing piperazine as inhibitors of PI3Kα.
Yin Y; Zhou Y; Sha S; Wu X; Wang SF; Qiao F; Song ZC; Zhu HL
Bioorg Chem; 2019 Nov; 92():103238. PubMed ID: 31499259
[TBL] [Abstract][Full Text] [Related]
9. Discovery of cinnoline derivatives as potent PI3K inhibitors with antiproliferative activity.
Tian C; Yang C; Wu T; Lu M; Chen Y; Yang Y; Liu X; Ling Y; Deng M; Jia Y; Zhou Y
Bioorg Med Chem Lett; 2021 Sep; 48():128271. PubMed ID: 34284105
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.
Zhang K; Lai F; Lin S; Ji M; Zhang J; Zhang Y; Jin J; Fu R; Wu D; Tian H; Xue N; Sheng L; Zou X; Li Y; Chen X; Xu H
J Med Chem; 2019 Aug; 62(15):6992-7014. PubMed ID: 31117517
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of benzo[d]imidazole derivatives as potential anti-cancer agents.
Alkahtani HM; Abbas AY; Wang S
Bioorg Med Chem Lett; 2012 Feb; 22(3):1317-21. PubMed ID: 22225635
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates containing sulfonamido as potential PI3Kα inhibitors.
Yin Y; Hu JQ; Wu X; Sha S; Wang SF; Qiao F; Song ZC; Zhu HL
Bioorg Med Chem; 2019 Jun; 27(11):2261-2267. PubMed ID: 31029551
[TBL] [Abstract][Full Text] [Related]
13. Structure optimization, synthesis, and biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)-quinazolin-4(3H)-one derivatives as potential multi-targeted anticancer agents via Aurora A/ PI3K/BRD4 inhibition.
Fan Y; Luo F; Su M; Li Q; Zhong T; Xiong L; Li M; Yuan M; Wang D
Bioorg Chem; 2023 Mar; 132():106352. PubMed ID: 36682147
[TBL] [Abstract][Full Text] [Related]
14. Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review.
Wang Y; Tortorella M
Eur J Med Chem; 2022 Jan; 228():114039. PubMed ID: 34894440
[TBL] [Abstract][Full Text] [Related]
15. Docking Studies and Antiproliferative Activities of 6-(3-aryl-2-propenoyl)-2(3H)- benzoxazolone Derivatives as Novel Inhibitors of Phosphatidylinositol 3-Kinase (PI3Kα).
Bilginer S; Bardaweel SK; Sabbah DA; Gul HI
Anticancer Agents Med Chem; 2021; 21(6):716-724. PubMed ID: 32767959
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity.
Xie XX; Li H; Wang J; Mao S; Xin MH; Lu SM; Mei QB; Zhang SQ
Bioorg Med Chem; 2015 Oct; 23(19):6477-85. PubMed ID: 26321603
[TBL] [Abstract][Full Text] [Related]
17. Development of anti-breast cancer PI3K inhibitors based on 7-azaindole derivatives through scaffold hopping: Design, synthesis and in vitro biological evaluation.
Yang C; Lu M; Chen Y; Xiang R; Qiu T; Jia Y; Yang Y; Liu X; Deng M; Ling Y; Zhou Y
Bioorg Chem; 2021 Dec; 117():105405. PubMed ID: 34649154
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW
Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461
[TBL] [Abstract][Full Text] [Related]
19. Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors.
Hei YY; Zhang SQ; Feng Y; Wang J; Duan W; Zhang H; Mao S; Sun H; Xin M
Bioorg Med Chem; 2019 Oct; 27(20):114930. PubMed ID: 31176568
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
